The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
Significance Of Soluble PD-L1 In Melanoma Patients
Funder
National Health and Medical Research Council
Funding Amount
$561,236.00
Summary
A class of new immunotherapy drugs called “antibodies of immune checkpoints” can lead to long-lasting melanoma regression, but they are only beneficial to a subset of patients. This project will potentially identify the increased expression of a protein called PD-L1 in the blood as a biomarker predictive of responses of melanoma patients to these new drugs. The results will be instructive for selection of patients for the treatment.
A 2:1 Randomised Phase II Study Of NivolUmab And Temozolomide Vs Temozolomide In Methylated Newly Diagnosed Elderly Glioblastoma (NUTMEG)
Funder
National Health and Medical Research Council
Funding Amount
$1,608,845.00
Summary
Radiotherapy and Temozolomide (TMZ) chemotherapy treatment for the brain tumour glioblastoma (GBM) is not as effective in elderly patients. If their tumour has a genetic marker called "methylated MGMT", TMZ does work relatively better and is often given alone. Elderly GBM patients with this marker will be randomly selected in this trial to have TMZ alone or TMZ + Nivolumab - a drug that assists the immune system to attack cancer.
Overcoming Resistance To Cancer Immunotherapy By Targeting MET-signaling In Neutrophils
Funder
National Health and Medical Research Council
Funding Amount
$447,375.00
Summary
Cancer is a leading cause of death in Australia. The human immune system is able to attack cancer cells. However, cancer cell can escape the destruction by cytotoxic cells. The development of novel immunotherapies has revolutionized cancer therapy, but only a subgroup of patients is responding. This research project aims to identify novel combinatorial therapies blocking immune suppressive neutrophils to improve anti-cancer immunity and survival of cancer patients.
Adoptive Cell Transfer Incorporating Vaccination (ACTIV) Therapy For Cancer
Funder
National Health and Medical Research Council
Funding Amount
$601,950.00
Summary
We have made a breakthrough in a new treatment for cancer that can destroy large tumours in mice. The treatment involves a transfusion of white blood cells and an injection of a vaccine. In this project, we will seek to understand how the treatment works, and apply it to human white blood cells in preparation for a clinical trial in cancer patients.
Cancers have thousands of mutations, so they should look a bit like a viral infection. If so, why doesn’t the immune system just destroy them outright, like they would a virus? We think the mutated proteins cause a ‘brake’ to be put on the anti-cancer immune response, and also that cancers subvert the anti-cancer attack by remaining hidden in the target zone. Unblocking these “brakes” might lead to new treatments.
Cancer Chemo-immunotherapy: Exploiting The Immunogenic Momentum Of Cytotoxic Chemotherapy
Funder
National Health and Medical Research Council
Funding Amount
$917,490.00
Summary
We recently found that chemotherapy has beneficial effects on the immune response against cancer rather than ill effects. Here we want to exploit this positive effect by combining different chemotherapeutics with immune-stimulating treatments in laboratory models. These studies will result in a better understanding of how chemotherapy influences the immune system, and may also result in new combinations that improve the effectiveness of cancer therapy.
Combining Immune Monitoring And Immunotherapy To Tackle Cytomegalovirus Infections In Solid Organ Transplant Patients
Funder
National Health and Medical Research Council
Funding Amount
$801,416.00
Summary
Clinical management of infectious complications in kidney and heart/lung transplant patients remains significant challenge. Although prophylactic/pre-emptive treatment with antiviral drugs have shown dramatic improvements in the control of these infections, long-term treatment with these drugs is associated with significant toxicity, the appearance of drug-resistant virus isolates and significant health cost. In this proposal we will develop novel strategies to identify high risk patients and tr ....Clinical management of infectious complications in kidney and heart/lung transplant patients remains significant challenge. Although prophylactic/pre-emptive treatment with antiviral drugs have shown dramatic improvements in the control of these infections, long-term treatment with these drugs is associated with significant toxicity, the appearance of drug-resistant virus isolates and significant health cost. In this proposal we will develop novel strategies to identify high risk patients and treat these patients with killer T cells.Read moreRead less
Identification Of CIS As A Potent Checkpoint In NK Cell-mediated Tumour Immunity
Funder
National Health and Medical Research Council
Funding Amount
$959,596.00
Summary
Cancer must evade detection by the immune system in order to develop. Natural Killer (NK) cells can detect and kill cancer cells. We have discovered a potent "checkpoint" in the NK cell activation pathway that desensitises NK cells to growth factors and switches off their activation and killer function. When this checkpoint is inhibited, NK cells are super activated and can prevent most types of cancer metastasis in mice. Targeting this checkpoint in humans could revolutionise cancer therapy.
Targeting Adenosine Mediated Immunosuppression To Enhance CAR T Cell Activity
Funder
National Health and Medical Research Council
Funding Amount
$633,447.00
Summary
The use of white blood cells genetically engineered to eradicate cancer cells specifically has been a major breakthrough in cancer treatment. These cells (CAR T cells) are very effective in blood cancers, but do not currently work well in other cancers. This is due to the immune suppressing nature of the cancer environment. I propose to use strategies to overcome this by genetically reprogramming the CAR T cells to be resistant to suppression by the cancer and therefore be more effective.
Generating Stronger And Smarter T Cells For Cancer Therapy
Funder
National Health and Medical Research Council
Funding Amount
$310,332.00
Summary
White blood cells from cancer patients can be modified in the laboratory to react against tumours. These cells can then be given back to the patient, which can sometimes cause cancer regression. However, often the white blood cells lack strength, or they lack the ability to distinguish between tumour and normal tissues of the body. In this project we seek to make stronger and smarter white blood cells that can deliver a lethal hit against tumours without damaging essential organs of the body.